论文部分内容阅读
目的：评价Ｇｅｍｃｉｔａｂｉｎｅ（中文译名：健择）单药及其与顺氯铵铂联合化疗方案治疗ＩＩ、ＩＶ期非小细胞肺癌（ＮＳＣＬＣ）的临床疗效及其不良反应。材料与方法：１健择单药研究：从１９９７年９月至１９９８年５月入选ＩＩ、ＩＶ期ＮＳＣＬＣ病人２１例，以前未接受过任何化疗、放疗。ＩＩ期病人１１例，ＩＶ期病人１０例。健择１０００ｍｇ／ｍ２，第１，８，１５天各注一次，每２８天为一疗程。２健择与顺氯铵铂联合化疗研究：从１９９７年１０月至１９９８年７月入选ＩＩ、ＩＶ期ＮＳＣＬＣ病人４８例，以前未接受过任何化疗、放疗。ＩＩ期病人１９例，ＩＶ期病人２９例。健择１０００ｍｇ／ｍ２，第１，８，１５天各注一次；顺氯铵铂１００ｍｇ／ｍ２，第一天用，每２８天为一疗程。结果：１健择单药研究：可评价疗效的有１９例，６例获部分缓解（ＰＲ），其中２例（１０５％）经４周以上复查证实。总有效率３１５％［９５％ＣＩ，９４％～４５１５％］。全组均可评价不良反应，少数病人发生轻微胃肠道反应、白细胞下降、血红蛋白下降和血小板下降，只有４８％（各１例）患者发生ＩＩ度的恶心呕吐及白细胞下降，有１例患者发生ＩＩ度感染。全组中位生存期６１３月。２?
OBJECTIVE: To evaluate the clinical efficacy and adverse reactions of Gemcitabine (Gemzard) and its combination with cisplatin in the treatment of stage II and IV non-small cell lung cancer (NSCLC). Materials and Methods: 1Study of Ginseng monotherapy: From September 1997 to May 1998, 21 patients with stage II and IV NSCLC were enrolled in the study. They had not received any chemotherapy or radiotherapy before. There were 11 patients with stage II disease and 10 patients with stage IV disease. Gemza 1000mg/m2, each one on the first, eighth and fifteen days, each 28 days is a course of treatment. (2) Combination chemotherapy with cisplatin and cisplatin: From October 1997 to July 1998, 48 patients with stage II and IV NSCLC were enrolled in the study. No chemotherapy or radiotherapy had been received before. There were 19 patients in stage II and 29 in stage IV. GemZe 1000mg/m2, once each on the 1st, 8th and 15th days; cisplatin platinum 100mg/m2, on the first day, every 28 days as a course of treatment. RESULTS: 1Study of Gemzard monotherapy: 19 cases were evaluated for efficacy, 6 cases were partially relieved (PR), and 2 cases (105%) were confirmed after more than 4 weeks of review. The total effective rate is 315% [95% CI, 94%~4515%]. Adverse reactions were evaluated in all groups. A small number of patients experienced mild gastrointestinal reactions, leukopenia, hemoglobin drop, and platelet drop. Only 4.8% of patients (one patient) developed grade II nausea and vomiting and leukopenia, and there was one case. The patient developed a grade II infection. The median survival time was 6 months and 13 months. 2?